Gene Expression Profiling in Type 1 Diabetes

Completed

Conditions studied: Type 1 Diabetes Mellitus

In brief

One of the goals of the Kansas City Diabetes Consortium is to identify and characterize genes and their products that are associated with T1DM. Characterization of such genes and their products can aid in developing new tools for risk assessment, development of new prevention strategies and monitoring progression of disease. Study design: Descriptive, basic science pilot study. The results of this pilot study will be used to help design a much larger study to address the importance of viral response and autoimmune diabetes.

Key facts

Study ID

NCT00330954

Run by

Children's Mercy Hospital Kansas City

People needed

64

Starts

2006-06-01

Expected to finish

2008-04-01

Last updated by the study team

2010-03-05

Who can join

Age: 7 and older, up to 14. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male and female subjects 7-14 years of age
• New onset T1DM
• Five years post onset of T1DM
• Participant in the TrialNet initiative and either antibody positive or antibody negative sibling control
• Body weight sufficient to tolerate an additional 15ml (1 tbsp) blood loss

You may not qualify if…

• Subjects who do not meet the criteria above
• Subjects who have received steroids or other immunosuppressive therapy within the 6 months prior to enrollment into the study

Where it is running

• Children's Mercy Hospital — Kansas City, Missouri, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.